Goldman Sachs
ABUS icon

Goldman Sachs’s Arbutus Biopharma ABUS Stock Holding History

Goldman Sachs’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-13,500
Closed -$176K – 7095
2014
Q2 		$176K Hold
13,500
– – ﹤0.01% 6291
2014
Q1 		$290K Buy
+13,500
New +$243K ﹤0.01% 5767

Other funds holding ABUS

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
WCM
Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Goldman Sachs's ABUS Position: Q1 2026 in Review

Goldman Sachs increased its Arbutus Biopharma (ABUS) stake by 49% in Q1 2026, buying an estimated $1.58M and bringing the position to 1,100,434 shares worth $4.95M. The position accounts for ﹤0.01% of the portfolio, ranked #3699.

Goldman Sachs first reported a position in ABUS in Q4 2013 and has held it in 48 quarters since. The position peaked at $9.87M in Q3 2025. 167 funds tracked by Wall St. Rank hold ABUS as of Q1 2026.

  • Goldman Sachs held 1,100,434 shares of Arbutus Biopharma worth $4.95M as of Q1 2026.
  • Goldman Sachs bought 361,854 Arbutus Biopharma shares in Q1 2026, an estimated $1.58M.
  • Arbutus Biopharma made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #3699 holding.
  • Goldman Sachs first reported a position in Arbutus Biopharma in Q4 2013 and has held it in 48 quarters since.
  • Goldman Sachs's Arbutus Biopharma position peaked at $9.87M in Q3 2025.
  • 167 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.